vs
Side-by-side financial comparison of Grand Canyon Education, Inc. (LOPE) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Grand Canyon Education, Inc. is the larger business by last-quarter revenue ($308.1M vs $196.9M, roughly 1.6× Pacira BioSciences, Inc.). On growth, Grand Canyon Education, Inc. posted the faster year-over-year revenue change (5.3% vs 5.1%). Grand Canyon Education, Inc. produced more free cash flow last quarter ($122.9M vs $43.5M). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (8.5% CAGR vs 5.9%).
Grand Canyon Education, Inc. (GCE) is an American for-profit corporation that provides services to universities, specializing in program development, online education, and operational support. Formerly affiliated with Grand Canyon University (GCU), a Christian university in Arizona, GCE became a separate publicly traded company in 2008.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
LOPE vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $308.1M | $196.9M |
| Net Profit | $86.7M | — |
| Gross Margin | — | 79.5% |
| Operating Margin | 35.1% | 1.2% |
| Net Margin | 28.1% | — |
| Revenue YoY | 5.3% | 5.1% |
| Net Profit YoY | 5.9% | — |
| EPS (diluted) | $3.13 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $308.1M | $196.9M | ||
| Q3 25 | $261.1M | $179.5M | ||
| Q2 25 | $247.5M | $181.1M | ||
| Q1 25 | $289.3M | $168.9M | ||
| Q4 24 | $292.6M | $187.3M | ||
| Q3 24 | $238.3M | $168.6M | ||
| Q2 24 | $227.5M | $178.0M | ||
| Q1 24 | $274.7M | $167.1M |
| Q4 25 | $86.7M | — | ||
| Q3 25 | $16.3M | $5.4M | ||
| Q2 25 | $41.5M | $-4.8M | ||
| Q1 25 | $71.6M | $4.8M | ||
| Q4 24 | $81.9M | — | ||
| Q3 24 | $41.5M | $-143.5M | ||
| Q2 24 | $34.9M | $18.9M | ||
| Q1 24 | $68.0M | $9.0M |
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% | ||
| Q1 24 | — | 71.6% |
| Q4 25 | 35.1% | 1.2% | ||
| Q3 25 | 6.9% | 3.5% | ||
| Q2 25 | 20.9% | 4.7% | ||
| Q1 25 | 30.4% | 1.2% | ||
| Q4 24 | 34.2% | 13.2% | ||
| Q3 24 | 20.2% | -82.8% | ||
| Q2 24 | 18.8% | 15.9% | ||
| Q1 24 | 30.8% | 7.9% |
| Q4 25 | 28.1% | — | ||
| Q3 25 | 6.2% | 3.0% | ||
| Q2 25 | 16.8% | -2.7% | ||
| Q1 25 | 24.8% | 2.8% | ||
| Q4 24 | 28.0% | — | ||
| Q3 24 | 17.4% | -85.1% | ||
| Q2 24 | 15.3% | 10.6% | ||
| Q1 24 | 24.8% | 5.4% |
| Q4 25 | $3.13 | $0.05 | ||
| Q3 25 | $0.58 | $0.12 | ||
| Q2 25 | $1.48 | $-0.11 | ||
| Q1 25 | $2.52 | $0.10 | ||
| Q4 24 | $2.83 | $0.38 | ||
| Q3 24 | $1.42 | $-3.11 | ||
| Q2 24 | $1.19 | $0.39 | ||
| Q1 24 | $2.29 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $111.8M | $238.4M |
| Total DebtLower is stronger | — | $372.2M |
| Stockholders' EquityBook value | $746.9M | $693.1M |
| Total Assets | $992.3M | $1.3B |
| Debt / EquityLower = less leverage | — | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $111.8M | $238.4M | ||
| Q3 25 | $97.3M | $246.3M | ||
| Q2 25 | $192.3M | $445.9M | ||
| Q1 25 | $144.5M | $493.6M | ||
| Q4 24 | $324.6M | $484.6M | ||
| Q3 24 | $263.6M | $453.8M | ||
| Q2 24 | $241.3M | $404.2M | ||
| Q1 24 | $196.2M | $325.9M |
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $746.9M | $693.1M | ||
| Q3 25 | $758.0M | $727.2M | ||
| Q2 25 | $778.0M | $757.8M | ||
| Q1 25 | $780.7M | $798.5M | ||
| Q4 24 | $783.9M | $778.3M | ||
| Q3 24 | $764.1M | $749.6M | ||
| Q2 24 | $759.2M | $879.3M | ||
| Q1 24 | $759.4M | $892.2M |
| Q4 25 | $992.3M | $1.3B | ||
| Q3 25 | $1.0B | $1.3B | ||
| Q2 25 | $1.0B | $1.5B | ||
| Q1 25 | $1.0B | $1.6B | ||
| Q4 24 | $1.0B | $1.6B | ||
| Q3 24 | $992.9M | $1.5B | ||
| Q2 24 | $992.7M | $1.6B | ||
| Q1 24 | $1.0B | $1.6B |
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $130.5M | $43.7M |
| Free Cash FlowOCF − Capex | $122.9M | $43.5M |
| FCF MarginFCF / Revenue | 39.9% | 22.1% |
| Capex IntensityCapex / Revenue | 2.5% | 0.1% |
| Cash ConversionOCF / Net Profit | 1.50× | — |
| TTM Free Cash FlowTrailing 4 quarters | $238.6M | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $130.5M | $43.7M | ||
| Q3 25 | $-48.6M | $60.8M | ||
| Q2 25 | $124.0M | $12.0M | ||
| Q1 25 | $67.6M | $35.5M | ||
| Q4 24 | $135.8M | $33.1M | ||
| Q3 24 | $-29.4M | $53.9M | ||
| Q2 24 | $98.6M | $53.2M | ||
| Q1 24 | $85.0M | $49.1M |
| Q4 25 | $122.9M | $43.5M | ||
| Q3 25 | $-58.3M | $57.0M | ||
| Q2 25 | $115.4M | $9.3M | ||
| Q1 25 | $58.7M | $26.9M | ||
| Q4 24 | $126.1M | $31.0M | ||
| Q3 24 | $-39.0M | $49.8M | ||
| Q2 24 | $89.6M | $51.6M | ||
| Q1 24 | $76.0M | $46.3M |
| Q4 25 | 39.9% | 22.1% | ||
| Q3 25 | -22.3% | 31.7% | ||
| Q2 25 | 46.6% | 5.1% | ||
| Q1 25 | 20.3% | 15.9% | ||
| Q4 24 | 43.1% | 16.6% | ||
| Q3 24 | -16.3% | 29.6% | ||
| Q2 24 | 39.4% | 29.0% | ||
| Q1 24 | 27.7% | 27.7% |
| Q4 25 | 2.5% | 0.1% | ||
| Q3 25 | 3.7% | 2.2% | ||
| Q2 25 | 3.5% | 1.5% | ||
| Q1 25 | 3.1% | 5.1% | ||
| Q4 24 | 3.3% | 1.1% | ||
| Q3 24 | 4.0% | 2.4% | ||
| Q2 24 | 3.9% | 0.9% | ||
| Q1 24 | 3.3% | 1.7% |
| Q4 25 | 1.50× | — | ||
| Q3 25 | -2.99× | 11.20× | ||
| Q2 25 | 2.98× | — | ||
| Q1 25 | 0.94× | 7.37× | ||
| Q4 24 | 1.66× | — | ||
| Q3 24 | -0.71× | — | ||
| Q2 24 | 2.83× | 2.82× | ||
| Q1 24 | 1.25× | 5.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LOPE
Segment breakdown not available.
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
